SIGA Technologies Inc SIGA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SIGA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $8.66
- Day Range
- $8.49–8.70
- 52-Week Range
- $4.22–10.00
- Bid/Ask
- $8.50 / $8.79
- Market Cap
- $614.23 Mil
- Volume/Avg
- 384,008 / 838,808
Key Statistics
- Price/Earnings (Normalized)
- 8.79
- Price/Sales
- 4.28
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 1.80%
Company Profile
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 45
- Website
- https://www.siga.com
Comparables
Valuation
|
Metric
|
SIGA
|
INVA
|
HLVX
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.79 | 9.13 | — |
Price/Book Value | 3.02 | 1.41 | 2.26 |
Price/Sales | 4.28 | 4.19 | — |
Price/Cash Flow | 9.01 | 7.85 | — |
Price/Earnings
SIGA
INVA
HLVX
Financial Strength
|
Metric
|
SIGA
|
INVA
|
HLVX
|
|---|---|---|---|
Quick Ratio | 3.16 | 7.28 | 10.37 |
Current Ratio | 4.42 | 9.03 | 10.62 |
Interest Coverage | — | 10.31 | −54.72 |
Quick Ratio
SIGA
INVA
HLVX
Profitability
|
Metric
|
SIGA
|
INVA
|
HLVX
|
|---|---|---|---|
Return on Assets (Normalized) | 37.36% | 14.79% | −34.03% |
Return on Equity (Normalized) | 45.10% | 29.29% | −42.52% |
Return on Invested Capital (Normalized) | 44.94% | 16.71% | −38.62% |
Return on Assets
SIGA
INVA
HLVX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Cmcwcvqrf | Tsdskjn | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Gkjwlhyhvq | Vgv | $68.9 Bil | |
HLN
| Haleon PLC ADR | Gpxgtqz | Gfn | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Mxdncgkm | Tdjp | $14.8 Bil | |
VTRS
| Viatris Inc | Rtgpmjxf | Cczt | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Mjjqcmv | Krqvx | $11.9 Bil | |
CTLT
| Catalent Inc | Mrfqyvv | Rzwsbtq | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Bypctkw | Clwx | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Mnyczqf | Slsdk | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Gmsnvdm | Ccxtyv | $3.5 Bil |